FDA Grants Accelerated Approval to J&J's EGFR·MET Targeted Subcutaneous Formulation 'Rybrevant Faspro' for Recurrent Head and Neck Cancer
Innovation in 2nd-line Treatment After 10 Years and Accelerated Approval
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to 'Rybrevant Faspro (amivantamab and hyaluronidase-lpuj),' developed by Janssen Biotech, a subsidiary of Johnson & Johnson (JNJ), as a monotherapy for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). This approval targets p16-negative, non-HPV adult patients who have failed both platinum-based chemotherapy and anti-PD-(L)1 immune checkpoint inhibitor treatments. As there has been no approved new drug in the second-line treatment area for this indication for the past 10 years, this is evaluated as opening a new horizon for the standard of care for end-stage patient groups with exhausted treatment alternatives. The FDA granted Priority Review and Breakthrough Therapy designation to this drug and decided on rapid authorization through Project Orbis, an international collaborative review program.
Combination of Bispecific Antibody and Subcutaneous Delivery Technology
Rybrevant Faspro is an innovative subcutaneous (SC) formulation that combines amivantamab, a bispecific antibody that simultaneously inhibits epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition (MET) receptor, with Halozyme's human recombinant hyaluronidase (Hyaluronidase-lpuj). While EGFR is overexpressed in more than 90% of HNSCC patients, a critical limitation existed where MET signaling pathways are activated upon single inhibitor administration, leading to drug resistance. Rybrevant Faspro fundamentally neutralizes this resistance mechanism by simultaneously binding to EGFR and MET on the cancer cell surface to induce degradation and trigger antibody-dependent cellular cytotoxicity (ADCC). Additionally, by applying a subcutaneous formulation that significantly reduces administration time and drastically lowers the risk of infusion-related reactions (IRR) compared to intravenous (IV) administration, it maximizes patient convenience and clinical efficiency.
Overwhelming OrigAMI-4 Clinical Data and Addressing Unmet Needs
In the Phase 1b/2 'OrigAMI-4 (NCT06385080)' trial, which served as the decisive evidence for this accelerated approval, Rybrevant Faspro demonstrated remarkable clinical efficacy in end-stage patient groups with extensive treatment histories. According to the Blinded Independent Central Review (BICR), it recorded an Overall Response Rate (ORR) of 42% (95% CI: 32%~52%) and a Complete Response (CR) rate of 15%. Compared to the ORR of 10%15% and median progression-free survival (mP2FS) of 23 months observed with existing standard treatments such as Cetuximab or single-agent chemotherapy, it showed nearly three times the therapeutic response. Furthermore, 56% of patients who responded to treatment maintained a Duration of Response (DOR) of 6 months or longer, objectively proving the robustness of the tumor suppression effect.
Market Expansion from Lung Cancer to Head and Neck Cancer and Regulatory Challenges
This indication acquisition for Rybrevant is a strategic turning point that successfully expanded the target market, previously limited to non-small cell lung cancer (NSCLC), into the global $2.8 billion head and neck cancer market. In the short term, Johnson & Johnson aims to preempt the patient group that has failed immunotherapy, and in the mid-to-long term, it is pursuing conversion to full approval and entry into the first-line treatment through the global confirmatory Phase 3 'OrigAMI-5' study. Due to the nature of accelerated approval, the challenge remains to clearly verify clinical benefits such as overall survival (OS) in follow-up Phase 3 trials, but considering the unmet second-line demand, the speed of commercial penetration is expected to be very rapid. This is expected to be recorded as a model case where Genmab's DuoBody platform and Halozyme's drug delivery technology successfully drove the lifecycle of a major blockbuster pipeline.
This approval serves as a catalyst to reshape the landscape of the global $2.8 billion head and neck squamous cell carcinoma (HNSCC) second-line treatment market, securing an objective response rate (ORR 42%) that exceeds the 10-15% response rate of existing standard treatments (Cetuximab/chemotherapy) by more than three times. From an investor's perspective, it expands the pipeline value of amivantamab, a non-small cell lung cancer blockbuster drug, across various solid tumors and acts as a direct positive for the royalty profitability of the original technology provider, Genmab, and the subcutaneous technology provider, Halozyme. For researchers and industry professionals, it is a major milestone that demonstrates, through large-scale clinical data, the efficacy of the bispecific antibody mechanism that overcomes chronic resistance in targeted therapies by simultaneously blocking EGFR and MET, as well as the clinical convenience of the subcutaneous formulation. In the mid-to-long term, depending on the results of the ongoing global confirmatory Phase 3 trial (OrigAMI-5), the conversion to full approval and deployment as a first-line combination therapy will become visible, with the pipeline's peak sales potential expected to be significantly upwardly adjusted to over $5 billion.